2012
DOI: 10.1074/jbc.m111.321190
|View full text |Cite
|
Sign up to set email alerts
|

Lung Cancer-derived Galectin-1 Enhances Tumorigenic Potentiation of Tumor-associated Dendritic Cells by Expressing Heparin-binding EGF-like Growth Factor

Abstract: Background: Communication between cancer cells and immune cells in their microenvironment leads to cancer progression. Results: Lung cancer-derived galectin-1 stimulates HB-EGF expression and triggers a release mechanism in tumor-associated dendritic cells that stimulates tumor cell growth and invasion. Conclusion: The galectin-1/HB-EGF cycle between cancer and dendritic cells enhances lung cancer progression. Significance: Galectin-1 is a potential therapeutic target for inhibiting tumor-promoting immune cell… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
26
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 37 publications
(28 citation statements)
references
References 33 publications
2
26
0
Order By: Relevance
“…Research from our laboratory has recognized an essential role for Gal1 as an immunoevasive mechanism in human and mouse melanoma (9). These observations were further confirmed in mouse lung adenocarcinoma (10,11), and in human cancers including Hodgkin lymphoma (12,13), neuroblastoma (14), head and neck squamous cell carcinoma (15), pancreatic carcinoma (16), glioma (17), and T-cell lymphoma (18), suggesting that targeting the Gal1-glycan axis might contribute to overcome immunosuppression and potentiate immunotherapeutic approaches. Interestingly, Gal1 was identified as a tumor-associated protein capable of delineating the metastatic potential of human breast carcinoma (19,20).…”
Section: Introductionsupporting
confidence: 53%
See 1 more Smart Citation
“…Research from our laboratory has recognized an essential role for Gal1 as an immunoevasive mechanism in human and mouse melanoma (9). These observations were further confirmed in mouse lung adenocarcinoma (10,11), and in human cancers including Hodgkin lymphoma (12,13), neuroblastoma (14), head and neck squamous cell carcinoma (15), pancreatic carcinoma (16), glioma (17), and T-cell lymphoma (18), suggesting that targeting the Gal1-glycan axis might contribute to overcome immunosuppression and potentiate immunotherapeutic approaches. Interestingly, Gal1 was identified as a tumor-associated protein capable of delineating the metastatic potential of human breast carcinoma (19,20).…”
Section: Introductionsupporting
confidence: 53%
“…This glycan-binding protein inhibits immune effector functions by shifting the balance toward a Th2 cytokine profile (9,23), by selectively deleting Th1 and Th17 cells (22) and by promoting the differentiation of tolerogenic dendritic cells (DC; refs. 11,14,26). Moreover, Gal1 facilitates the expansion of IL-10-producing T regulatory type-1 (Tr1) cells (23,26,27) and contributes to the immunosuppressive activity of CD4…”
Section: Introductionmentioning
confidence: 99%
“…EGFR is activated in tumor-associated endothelial cells, but not in endothelial cells within uninvolved organ regions, suggesting that EGF receptor activation and expression of EGF receptors on endothelial cells is conditioned by the organ microenvironment (Kim et al , 2003). It is also believed that cancer cells secrete EGF-like growth factors that can act directly on endothelial cells (Kuo et al , 2012). The microenvironment can also send signals to tumor cells.…”
Section: Egfr Signaling In Normal and Transformed Cellsmentioning
confidence: 99%
“…Conversely, DC isolated from non-small cell lung tumors can over express immuno-regulatory molecules such as PD-L1 52 and CD276 (a member of the B7 family also known as B7-H3) 53 and these are likely to be associated with a poor prognosis. Lung cancers can secrete galectin-1 that enhances DC production of heparin binding EGF-like growth factor which then increases cancer progression 54 . There is much interest in utilizing DC-based vaccines in combination with activated killer T-cells to enhance the host anti-tumor response in lung cancer.…”
Section: Lung Cancer and Mesotheliomamentioning
confidence: 99%